Inventiva Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Andrew Obenshain

Chief Executive Officer (CEO)

€10.8m

Compensación total

Porcentaje del salario del CEO	1.41%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • May 15

Inventiva's Speculative Upside Through MASH Is Promising

Summary Inventiva is now essentially a lanifibranor bet. Their prospects hinge on the upcoming Phase 3 NATiV3 readout, which we should get by Q4 2026. In my view, lanifibranor seems relatively differentiated after its Phase 2b results. Management is narrowing its focus solely on this MASH asset. IVA’s balance sheet has sufficient financing to reach that readout. But please bear in mind that it’s a binary outcome. I believe that, if lanifibranor succeeds, the upside could be considerable. Conversely, if they fail, their runway would be tighter with a failed asset. On balance, IVA is the quintessential high-risk, high-reward biotech stock. But, given its promising trial data, the setup is compelling. Read the full article on Seeking Alpha

Seeking Alpha • Jul 08

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Summary Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification. The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035. It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs. Read the full article on Seeking Alpha

Seeking Alpha • Feb 22

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanifibranor in combination with Jardiance for the treatment of patients with NASH and Type 2 Diabetes, expected Q1 of 2024. The global non-alcoholic steatohepatitis treatment market size is expected to reach $48.3 billion by the end of 2035. Several competitors in NASH, but the company might overcome most with the fact that oral administration can be given; Another option to beat the competition would be through combination treatments such as lanifibranor + Jardiance. Read the full article on Seeking Alpha

Seeking Alpha • Sep 21

Inventiva, Sino Biopharm sign licensing pact to develop, commercialize NASH treatment

France-based clinical-stage biopharma Inventiva (NASDAQ:IVA) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor. As per the deal, Inventiva (IVA) will get a $12M upfront payment along with $5M in short term potential milestone payments. IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties. Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement. IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA. U.S.-listed shares of IVA -2.8% to $3.82 after hours.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Andrew Obenshain en comparación con los beneficios de Inventiva?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2025	€11m	€152k	-€354m

Compensación vs. Mercado: La compensación total de Andrew($USD12.50M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.69M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Andrew con los resultados de la empresa.

CEO

Andrew Obenshain (52 yo)

less than a year

Permanencia

€10,832,244

Compensación

Mr. Andrew Obenshain serves as Chief Executive Director at Inventiva S.A. since October 01, 2025 and served as its Director. He has been the Director of bluebird bio, Inc. since November 2021 and served as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Andrew Obenshain	Chief Executive Officer	less than a year	€10.83m	sin datos
Pierre Broqua	Co-Founder	15.4yrs	€411.80k	1.65% $ 12.9m
Jean Volatier	Executive VP Finance & Corporate Social Responsibility	less than a year	€1.47m	0.11% $ 867.8k
Martine Zimmermann	Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs	less than a year	€4.19m	sin datos
Jason Campagna	President of Research & Development and Chief Medical Officer	less than a year	€2.82m	sin datos
Axel-Sven Malkomes	Chief Financial Officer	less than a year	sin datos	sin datos
Susan Coles	Chief Legal Officer	less than a year	sin datos	sin datos
Pamela Herbster	Chief People Officer	less than a year	sin datos	sin datos
Pascaline Clerc	Executive Vice President of External and Corporate Affairs	2.7yrs	sin datos	0.0088% $ 68.5k
Nazira Amra	Chief Commercial Strategy Officer	no data	sin datos	sin datos

0.7yrs

Permanencia media

59.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IVA no se considera experimentado ( 0.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mark Pruzanski	Independent Chairman	1.5yrs	€14.42m	sin datos
Annick Schwebig	Independent Director	9.3yrs	€141.90k	0.0015% $ 11.5k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	sin datos
Andrew Shenker	Member of Scientific Advisory Board	6.6yrs	sin datos	sin datos
Arun Sanyal	Member of Scientific Advisory Board	5.8yrs	sin datos	sin datos
Heinz Maeusli	Independent Director	7.1yrs	€135.60k	sin datos
Sven Francque	Member of Scientific Advisory Board	no data	sin datos	sin datos
Manal Abdelmalek	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kenneth Cusi	Member of Scientific Advisory Board	no data	sin datos	sin datos
Glen Clack	Member of Scientific Advisory Board	no data	sin datos	sin datos
Gérard Zalcman	Scientific Advisory Board Member	no data	sin datos	sin datos
Elisabetta Bugianesi	Member of the Scientific Advisory Board	4.4yrs	sin datos	sin datos

6.2yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: La junta directiva de IVA se considera experimentada (6.2 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/06/10 00:24
Precio de las acciones al final del día	2026/06/10 00:00
Beneficios	2025/12/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Inventiva S.A. está cubierta por 22 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Eliana Merle	Barclays
Edward Nash	Canaccord Genuity
Etzer Darout	Guggenheim Securities, LLC

Inventiva Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva Announces Executives Changes

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva S.A., Annual General Meeting, May 22, 2025

Recent updates

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.

Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners Limited

Inventiva S.A., Annual General Meeting, Jun 30, 2026

Inventiva's Speculative Upside Through MASH Is Promising

Inventiva Announces Executives Changes

Inventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026

Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.

Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.

Inventiva Announces CEO Changes

Inventiva Announces Executive Appointments

Inventiva Announces the Publication in Journal of Hepatology Reports on Results of Lanifibranor Treatment on Liver Sinusoidal Endothelial Cells in Patients with MASLD/MASH and in Preclinical Models of the Disease

Inventiva Announces the Appointment of Renée Aguiar-Lucander to Its Board of Directors

Inventiva Announces the Publication in Clinical Gastroenterology and Hepatology of Its Analysis of New Biomarker Signatures Predictive of Histological Response in Patients with Mash Treated with Lanifibranor

Inventiva S.A., Annual General Meeting, May 22, 2025

Inventiva S.A. and Hepalys Pharma, Inc. Announce the Initiation of the Clinical Development Program of Lanifibranor in Japan

Inventiva S.A. to Report First Half, 2025 Results on Sep 25, 2025

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis